Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Cash & Equivalents for 7 consecutive years, with $287.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 48.67% year-over-year to $287.4 million, compared with a TTM value of $287.4 million through Dec 2025, down 48.67%, and an annual FY2025 reading of $287.4 million, down 48.67% over the prior year.
  • Cash & Equivalents was $287.4 million for Q4 2025 at Keros Therapeutics, down from $693.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $720.5 million in Q1 2025 and bottomed at $215.6 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $376.5 million, with a median of $305.0 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 368.11% in 2021, then plummeted 48.67% in 2025.
  • Year by year, Cash & Equivalents stood at $230.0 million in 2021, then grew by 21.3% to $279.0 million in 2022, then increased by 18.67% to $331.1 million in 2023, then surged by 69.09% to $559.9 million in 2024, then tumbled by 48.67% to $287.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for KROS at $287.4 million in Q4 2025, $693.5 million in Q3 2025, and $690.2 million in Q2 2025.